These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29317410)

  • 1. Derivation of a System-Independent
    Chaudhry A; Chung G; Lynn A; Yalvigi A; Brown C; Ellens H; O'Connor M; Lee C; Bentz J
    Drug Metab Dispos; 2018 Mar; 46(3):279-290. PubMed ID: 29317410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.
    Bentz J; Ellens H
    Methods Mol Biol; 2021; 2342():737-763. PubMed ID: 34272715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.
    Agnani D; Acharya P; Martinez E; Tran TT; Abraham F; Tobin F; Ellens H; Bentz J
    PLoS One; 2011; 6(10):e25086. PubMed ID: 22028772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
    Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
    PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.
    Meng Z; Ellens H; Bentz J
    Drug Metab Dispos; 2017 Feb; 45(2):190-197. PubMed ID: 27856526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
    Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
    Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
    Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
    Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.
    Li YH; Bi HC; Huang L; Jin J; Zhong GP; Zhou XN; Huang M
    Acta Pharmacol Sin; 2014 Feb; 35(2):283-91. PubMed ID: 24362330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
    Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
    Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
    Bentz J; O'Connor MP; Bednarczyk D; Coleman J; Lee C; Palm J; Pak YA; Perloff ES; Reyner E; Balimane P; Brännström M; Chu X; Funk C; Guo A; Hanna I; Herédi-Szabó K; Hillgren K; Li L; Hollnack-Pusch E; Jamei M; Lin X; Mason AK; Neuhoff S; Patel A; Podila L; Plise E; Rajaraman G; Salphati L; Sands E; Taub ME; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yabut J; Yamagata T; Zhang L; Ellens H
    Drug Metab Dispos; 2013 Jul; 41(7):1347-66. PubMed ID: 23620485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
    van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
    Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the IPEC-J2 MDR1 (iP-gp) cell line as a tool for identification of P-gp substrates.
    Ozgür B; Saaby L; Langthaler K; Brodin B
    Eur J Pharm Sci; 2018 Jan; 112():112-121. PubMed ID: 29146563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine.
    Chae HW; Kim IW; Jin HE; Kim DD; Chung SJ; Shim CK
    Arch Pharm Res; 2008 Jan; 31(1):103-10. PubMed ID: 18277615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural model for the mass action kinetic analysis of P-gp mediated transport through confluent cell monolayers.
    Bentz J; Ellens H
    Methods Mol Biol; 2014; 1113():289-316. PubMed ID: 24523118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
    J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers.
    Meng Z; Le Marchand S; Agnani D; Szapacs M; Ellens H; Bentz J
    Drug Metab Dispos; 2017 Feb; 45(2):145-151. PubMed ID: 27856525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M; Nakajima M; Yamazaki H; Yokoi T
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein-mediated transport in a mucus-supplemented Caco-2 cell model in the presence of different surfactants.
    Jakobsen S; Gaenaelle Gé L; Pedersen M; Griffin BT; Holm R; Uhd Nielsen C
    Int J Pharm; 2022 Aug; 624():121885. PubMed ID: 35690306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.